echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > BMJ: Sintilimab combined with chemotherapy as first-line therapy significantly prolongs survival in patients with advanced/metastatic esophageal squamous cell carcinoma

    BMJ: Sintilimab combined with chemotherapy as first-line therapy significantly prolongs survival in patients with advanced/metastatic esophageal squamous cell carcinoma

    • Last Update: 2022-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Esophageal squamous cell carcinoma is the main subtype of esophageal cancer, accounting for about 90% of all esophageal cancers


    Currently, first-line therapy for patients with advanced or metastatic ESCC is limited to platinum-based chemotherapy


    To evaluate the efficacy and safety of sintilimab vs placebo in combination with chemotherapy (cisplatin + paclitaxel or cisplatin + 5-fluorouracil) as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma


    This is a multicenter, randomized, double-blind phase 3 trial conducted at 66 sites in China and 13 sites abroad, recruiting patients aged 18 years and older with advanced or metastatic esophageal squamous cell carcinoma who have not received systemic therapy


    Between December 14, 2018, and April 9, 2021, a total of 659 patients were recruited and randomized into two groups: 327 in the sintilimab group and 332 in the placebo group




    Both in the overall population and in patients with a PD-L1 expression combined positive score of ≥10, patients in the sintilimab group had longer overall survival compared with placebo in both the overall population and PD- In patients with L1 expression combined with a positive score of ≥10, the overall survival of patients in the sintilimab group was significantly longer compared with the placebo group.



    In conclusion, compared with placebo combined with chemotherapy, sintilimab combined with chemotherapy as first-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma can significantly prolong their overall survival and progression-free survival


    Compared with placebo plus chemotherapy, sintilimab plus chemotherapy as first-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma significantly prolongs overall survival and progression-free survival


    Original source:

    Original source:

    Lu Zhihao, Wang Junye, Shu Yongqian et al.


    Lu Zhihao, Wang Junye, Shu Yongqian et al.
    Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
    [J ] .
    BMJ, 2022, 377: e068714.


    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.